Author : Jeenat Aslam 1
Date of Publication :16th January 2019
Abstract: The rising amount of biomedical information in chemistry and life sciences needs the progress of latest techniques and viewpoint for their use. Now in this manuscript, we shortly talk about various dares and chance of this high-speed increasing region of investigate with center of attention on those to be inscribed within the BIGCHEM plan. The manuscript begins with a short explanation of various obtainable assets for “Big Data” in chemistry and analysis of the significance of information value. The „big data‟ idea acts a gradually more significant part in numerous scientific fields. The Big data requires more than remarkable high volumes of information that turn into existing. Diverse basis distinguishing big data must be cautiously calculated in computational information mining, as we talk about herein concentrating on medicinal chemistry. It is a logical regulation where big data is starting to appear and give latest chances. For paradigm, the various medicines capacity to exclusively act together with numerous objects, described as promiscuity, forms the molecular origin of polypharmacology, a warm subject in drug finding. We explain that the able examination of billions of molecules needs the growth of smart plans. Furthermore, the problem of protected data giving out without reveals chemical form which is vital to permit bi-party or multi-party information distribution. Information giving out is significant in the situation of the modern development of “open innovation” in pharmaceutical trade, which has led to not merely more data distribution between academics and pharma companies but also the known as “precompetitive” teamwork among pharma companies. At the conclusion we emphasize the significance of learning in “Big Data” for additional growth of this field
- https://en.wikipedia.org/wiki/Bigdata (10June 2016)
- B. Chen, A. J. Butte, Clin. Pharmacol. Ther. 2016, 99, 285 – 297.
- S. Kim, P. A. Thiessen, E. E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. He, S. He, B. A. Shoemaker, J. Wang, B. Yu, J. Zhang, S. H. Bryant, Nucleic Acids Res. 2016, 44, D1202 – 1213.
- G. Papadatos, A. Gaulton, A. Hersey, J. P. Overington, J. Comput. Aided. Mol. Des. 2015, 29, 885 – 896
- I. V. Tetko, D. Lowe, A. J. Williams, J. Cheminform. 2016, 8, 2  Al-Lazikani B, Workman P. Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome. Future Med. Chem. 8(14), 1711–1716 (2016).
- Bajorath J, Jenkins J, Overington J, Walters WP. Drug discovery and development in the era of big data. Future Med. Chem. 8(15), 1807–1813 (2016)
- Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery: miniperspective. J. Med. Chem. 57(19), 7874–7887 (2014).